Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula (I) are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.

Abstract: Compounds of general formula (Ia), compounds of general formula (Ia?), compounds of general formula (Ib), compounds of general formula (Ib?), compounds of general formula (I), compounds of general formula (I?), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, R6, R8, R9, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds of the disclosure.

Abstract: Compounds of general formula (Ia), compounds of general formula (Ia?), compounds of general formula (Ib), compounds of general formula (Ib?), compounds of general formula (I), compounds of general formula (I?), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, R6, R8, R9, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds of the disclosure.

Abstract: Compounds of general formula (Ia), compounds of general formula (Ia?), compounds of general formula (Ib), compounds of general formula (Ib?), compounds of general formula (I), compounds of general formula (I?), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, R6, R8, R9, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds of the disclosure.

Abstract: The invention provides a method for estimating a battery capacity of an electronic device. When a current or an average current of the battery is zero, a reference capacity is inquired from a look-up table based on a voltage of the battery. When a previously remaining capacity is greater than a reference capacity, a deduction process of a self-consumable capacity is performed one or more times for a previously recorded remaining capacity to obtain a new recorded remaining capacity smaller than the reference capacity. When the current of the battery is less than zero, a deduction process of a count capacity of discharging is performed one or more times for the previously recorded remaining capacity until a power of the battery is exhausted to obtain a first offset capacity. The first offset capacity is deducted from a previously recorded full charge capacity to estimate a new full charge capacity.

Abstract: An electric hammer comprising an electric motor, a spindle coupled to the electric motor and adapted to be driven by the electric motor, an impacting member adapted to be coupled to the spindle and driven by the spindle, and a direction changing device adapted to be coupled with the impacting member. The direction changing device changes the direction of movement of the impacting member such that the kinetic energy of the impacting member is provided to an energy storage device for accumulation after the change in the direction of movement. The energy storage device is adapted to return the accumulated energy to the impacting member such that the latter generates an impacting force to an output member.

Abstract: Disclosed are a device and a method for testing a battery equalization circuit.

Abstract: A class of polycyclic compounds of general formula (I), of general formula (I?), or of general formula (I?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.

Abstract: A class of polycyclic compounds of general formula (I), of general formula (I?), or of general formula (I?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.

Abstract: A class of polycyclic compounds of general formula (I), of general formula (I?), or of general formula (I?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.

Abstract: Compounds of general formula (Ia), compounds of general formula (Ia?), compounds of general formula (Ib), compounds of general formula (Ib?), compounds of general formula (I), compounds of general formula (I?), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, R6, R8, R9, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds of the disclosure.

Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula (I) are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.

Abstract: A class of polycyclic compounds of general formula (I), of general formula (I?), or of general formula (I?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.

Abstract: A system and a method for controlling a ducted air-conditioning system are provided. The system comprises: a temperature controller, configured to generate a first control instruction for controlling the ducted air-conditioning system; a mobile terminal, configured to generate a second control instruction for controlling the ducted air-conditioning system; and a conversion device, connected between the ducted air-conditioning system and the temperature controller, communicating with the mobile terminal via wireless communication, and configured to receive the first control instruction from the temperature controller, and transmit the first control instruction to the ducted air-conditioning system, and to receive the second control instruction from the mobile terminal, convert the second control instruction into a third control instruction, and transmit the third control instruction to the ducted air-conditioning system.

Abstract: A system for deploying a Service-Oriented Architecture (SOA) deployment environment model and a system for modifying a deployed SOA deployment environment model. In the deploying system, deployment of the SOA deployment environment model is realized by acquiring a task list including tasks for deploying elements of the model, associating the tasks in the task list with the elements, and executing the tasks to deploy the elements of the model. In the modifying system, modification of the SOA deployment environment model is realized by acquiring a task list including tasks for modifying elements of the model, associating the tasks in the task list with the elements, and executing the tasks to modify the elements. Thus, the deployment of the SOA deployment environment model and the modification of the deployed SOA deployment environment model may be realized in a simple and easy-to-implement manner.

Abstract: A method for deploying a Service-Oriented Architecture (SOA) deployment environment model and a method for modifying a deployed SOA deployment environment model. In the deploying method, deployment of the SOA deployment environment model is realized by acquiring a task list including tasks for deploying elements of the model, associating the tasks in the task list with the elements, and executing the tasks to deploy the elements of the model. In the modifying method, modification of the SOA deployment environment model is realized by acquiring a task list including tasks for modifying elements of the model, associating the tasks in the task list with the elements, and executing the tasks to modify the elements. Thus, the deployment of the SOA deployment environment model and the modification of the deployed SOA deployment environment model may be realized in a simple and easy-to-implement manner.

Abstract: The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

Abstract: A uniform approach for web service discovery is provided through common auto-discovery logic for cloud-based or enterprise-based deployments for a specific web service. Appropriate credentials may be applied employing a uniform method using an appropriate authentication scheme for on-premise, fully hosted, or partially hosted auto-discovered web services. A common interface may be implemented even if the protocols for discovery differ from service to service or between cloud-based deployment and enterprise-based deployment for the same service. Web service locations auto-discovered through different protocols may be cached for subsequent use.

Abstract: A method and apparatus is described for rendering web pages by a wireless device in order to reduce an amount of data transmitted over-the-air to the wireless device. In one embodiment, a method is performed by a server, comprising receiving a markup language document from a web server via a network interface, the markup language document corresponding to a web page. Next, the markup language document is parsed into a number of blocks by a processor, each of the blocks comprising code representing original content of the web page. Then, the processor creates one or more replacement blocks, each of the replacement blocks corresponding to a respective one of the blocks, each of the replacement blocks comprising code representing substituted content of the web page. Some of the blocks and at least one of the replacement blocks are then sent to a wireless device for rendering.